using student t-test (*p,0.05). GraphPad Prism 5.0 (San Diego, CA) was used to perform all the statistical analysis. Supporting Information Figure S1 Quantitative analysis of SSTR postive neurons for receptor specific changes in SSTR1/52/2 and R6/2 mice strains. Note receptor specific changes in the numbers of SSTR1–5 positive neurons in SSTR1/52/2and R6/2 mice compared to the respective wt. Data presented as mean 6 SD for neuronal quantification (SSTR1/52/2, n = 5 and R6/2 mice, n = 3) in comparison to wt mice brain, *P,0.05, ** P,0.01. (TIF) Figure S2 Downstream signalling pathways are differentialy regulated in R6/2 and SSTR1/52/2 mice. Tissue lysate prepared from striatum of R6/2 and SSTR1/52/2 mice brain was fractionated on 10% SDS PAGE and membrane was blotted for References 1. de la Monte SM, Vonsattel JP, Richardson EP, Jr. (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington’s disease. J Neuropathol Exp Neurol 47: 516–525. 2. Giampa C, DeMarch Z, D’Angelo V, Morello M, Martorana A, et al. (2006) Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington’s disease. Eur J Neurosci 23: 11–20. 3. The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72: 971–983. 4. Kumar U, Asotra K, Patel SC, Patel YC (1997) Expression of NMDA Receptor- 1 (NR1) and Huntingtin in Striatal Neurons Which Colocalize Somatostatin, Neuropeptide Y, and NADPH Diaphorase: A Double-Label Histochemical and Immunohistochemical Study. Experimental Neurology 145: 412–424. 5. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR (1997) The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60: 1202–1210. 6. Gusella JF, MacDonald ME (2000) Molecular genetics: unmasking polygluta- mine triggers in neurodegenerative disease. Nat Rev Neurosci 1: 109–115. 7. Cicchetti F, Parent A (1996) Striatal interneurons in Huntington’s disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons. Mov Disord 11: 619–626. 8. Ferrante RJ, Kowall NW, Beal MF, Richardson EP, Jr., Bird ED, et al. (1985) Selective sparing of a class of striatal neurons in Huntington’s disease. Science 230: 561–563. 9. Huang Q, Zhou D, Sapp E, Aizawa H, Ge P, et al. (1995) Quinolinic acid- induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington’s disease. Neuroscience 65: 397–407. 10. Kiyama H, Seto-Ohshima A, Emson PC (1990) Calbindin D28K as a marker for the degeneration of the striatonigral pathway in Huntington’s disease. Brain Res 525: 209–214. 11. Sun Z, Wang HB, Deng YP, Lei WL, Xie JP, et al. (2005) Increased calbindin- D28k immunoreactivity in striatal projection neurons of R6/2 Huntington’s disease transgenic mice. Neurobiol Dis 20: 907–917. 12. Li SH, Li XJ (2004) Huntingtin-protein interactions and the pathogenesis of Huntington’s disease. Trends Genet 20: 146–154. 13. Albin RL, Young AB, Penney JB, Handelin B, Balfour R, et al. (1990) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med 322: 1293–1298. 14. Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D’Amato C, et al. (1988) NMDA receptor losses in putamen from patients with Huntington’s disease. Science 241: 981–983. 15. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12: 529–540. 16. Ozawa S, Kamiya H, Tsuzuki K (1998) Glutamate receptors in the mammalian central nervous system. Prog Neurobiol 54: 581–618. 17. Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, et al. (1999) Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 72: 1890–1898. 18. Fan MM, Raymond LA (2007) N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington’s disease. Prog Neurobiol 81: 272–293. 19. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, et al. (2009) Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15: 1407–1413. Somatostatin Receptor 1/5 Knockout and R6/2 Mice total and phosphorylated ERK1/2 and PI3K and PKC-a. The status of p-ERK1/2 is not changed in R6/2 and SSTR1/52/2 mice striatum (a). Note the decreased expression level of PI3K (110 kDa) in R6/2 mice whereas SSTR1/52/2 mice brain exhibited increased PI3K expression (b). In contrast PKC-a (80 kDa) decreased in R6/2 and SSTR1/52/2 mice brain (c). Data presented as mean 6 SD (SSTR1/52/2, n = 5 and R6/2 mice, n = 3) in comparison to wt mice brain, *P,0.05, ** P,0.01, ***P,0.001. (TIF) Author Contributions Conceived and designed the experiments: PSR BRS CFB UK. Performed the experiments: PSR. Analyzed the data: PSR GK. Contributed reagents/ materials/analysis tools: MN S-HL CFB. Wrote the paper: PSR UK. 20. Beal MF, Ferrante RJ, Swartz KJ, Kowall NW (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease. J Neurosci 11: 1649–1659. 21. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, et al. (1986) Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 321: 168–171. 22. Aronin N, Cooper PE, Lorenz LJ, Bird ED, Sagar SM, et al. (1983) Somatostatin is increased in the basal ganglia in Huntington disease. Ann Neurol 13: 519–526. 23. Beal MF, Bird ED, Langlais PJ, Martin JB (1984) Somatostatin is increased in the nucleus accumbens in Huntington’s disease. Neurology 34: 663–666. 24. Dawbarn D, De Quidt ME, Emson PC (1985) Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington’s disease. Brain Res 340: 251–260. 25. Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ, Jr., Kizer JS (1983) Regional brain concentrations of neuropeptides in Huntington’s chorea and schizophrenia. Science 221: 972–975. 26. Vincent SR, Johansson O (1983) Striatal neurons containing both somatostatin- and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH- diaphorase activity: a light and electron microscopic study. J Comp Neurol 217: 264–270. 27. Patel SC, Papachristou DN, Patel YC (1991) Quinolinic acid stimulates somatostatin gene expression in cultured rat cortical neurons. J Neurochem 56: 1286–1291. 28. Koh JY, Peters S, Choi DW (1986) Neurons containing NADPH-diaphorase are selectively resistant to quinolinate toxicity. Science 234: 73–76. 29. Augood SJ, McGowan EM, Emson PC (1994) Expression of N-methyl-D- aspartate receptor subunit NR1 messenger RNA by identified striatal somatostatin cells. Neuroscience 59: 7–12. 30. Chen Q, Veenman CL, Reiner A (1996) Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuro- science 73: 715–731. 31. Kumar U (2008) Somatostatin in medium-sized aspiny interneurons of striatum is responsible for their preservation in quinolinic acid and N-methyl-D-asparate- induced neurotoxicity. J Mol Neurosci 35: 345–354. 32. Dawson VL, Kizushi VM, Huang PL, Snyder SH, Dawson TM (1996) Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J Neurosci 16: 2479–2487. 33. Patel YC (1999) Somatostatin and Its Receptor Family. Frontiers in Neuroendocrinology 20: 157–198. 34. Grant M, Collier B, Kumar U (2004) Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem 279: 36179–36183. 35. Grant M, Patel RC, Kumar U (2004) The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem 279: 38636–38643. 36. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, et al. (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288: 154–157. 37. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, et al. (2002) Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277: 19762–19772. 38. Binaschi A, Bregola G, Simonato M (2003) On the role of somatostatin in seizure control: clues from the hippocampus. Rev Neurosci 14: 285–301. 39. De Wied D, Sigling HO (2002) Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 4: 453–468. PLoS ONE | www.plosone.org 11 September 2011 | Volume 6 | Issue 9 | e24467